Cara Therapeutics (CARA, Financial) has disclosed plans for a structural change to its stock by implementing a 1-for-3 reverse stock split. This adjustment will see its common shares restructured, effectively reducing the total number of shares while maintaining the overall value.
The new arrangement will coincide with a rebranding effort, as the company transitions to Tvardi Therapeutics. Consequently, the shares are set to commence trading under the updated name, Tvardi Therapeutics, and the new ticker symbol, "TVRD," starting from the market opening on Wednesday, April 16. This shift aligns with the anticipated completion of Cara’s merger with Tvardi Therapeutics.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Cara Therapeutics Inc (CARA, Financial) is $12.24 with a high estimate of $12.24 and a low estimate of $12.24. The average target implies an upside of 113.24% from the current price of $5.74. More detailed estimate data can be found on the Cara Therapeutics Inc (CARA) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Cara Therapeutics Inc's (CARA, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cara Therapeutics Inc (CARA, Financial) in one year is $4.80, suggesting a downside of 16.38% from the current price of $5.74. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cara Therapeutics Inc (CARA) Summary page.
